Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru
Authors
Keywords
Pneumococcal disease, Pneumococcal vaccines, Cost-effectiveness, Acute otitis media, Non-typeable <em class=EmphasisTypeItalic >Haemophilus influenzae</em>, Peru
Journal
BMC PUBLIC HEALTH
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-10-30
DOI
10.1186/1471-2458-13-1025
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
- (2012) Arto A Palmu et al. LANCET
- Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children
- (2012) Carlos Castañeda-Orjuela et al. VACCINE
- Epidemiology of acute otitis media in children of Latin America and the Caribbean: A systematic review and meta-analysis
- (2011) Ariel Bardach et al. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
- Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina
- (2011) Analía Urueña et al. VACCINE
- Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente
- (2011) Emilio Muciño-Ortega et al. VALUE IN HEALTH
- Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise
- (2011) Gerhart Knerer et al. JOURNAL OF MEDICAL ECONOMICS
- Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
- (2010) William P Hausdorff et al. BMC Pediatrics
- Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
- (2010) Sean T. Duggan DRUGS
- Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: A multicountry analysis
- (2010) Sandra E. Talbird et al. VACCINE
- Modelling the effect of conjugate vaccines in pneumococcal disease: Cohort or population models?
- (2010) Baudouin Standaert et al. VACCINE
- 10-valent pneumococcal nontypeableHaemophilus influenzaePD conjugate vaccine: Synflorix™
- (2009) Roman Prymula et al. Expert Review of Vaccines
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
- (2009) Katherine L O'Brien et al. LANCET
- The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity
- (2009) Nancy Bermal et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Efficacy of an 11-Valent Pneumococcal Conjugate Vaccine Against Radiologically Confirmed Pneumonia Among Children Less Than 2 Years of Age in the Philippines
- (2009) Marilla G. Lucero et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine
- (2009) Timo Vesikari et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C
- (2008) In H. Park et al. JOURNAL OF INFECTIOUS DISEASES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started